Speaker: David Sallman

0:02:23

Improving treatment for patients with TP53-mutated myeloid malignancies

1:38:33

MDS 2023: PS 7 - Non Targeted Approaches for HR MDS

0:02:25

A final update of ENHANCE: reflecting on the negative read-out of the study

0:03:39

Promising agents under investigation for the treatment of MDS and ongoing trials in this space

0:01:13

Challenges in risk stratifying LR-MDS: insights into genetic upstaging and early transplant

0:03:09

Promising treatment approaches for patients with MDS

0:02:40

Recent advances in CAR-T therapy for MDS

0:01:39

Evaluating the impact of MRD by error-corrected NGS on patients with AML treated with CPX-351

0:01:48

A Phase I/Ib dose escalation & expansion study of CPX-351 + gemtuzumab ozogamicin in ND AML

0:01:10

Addressing leukemic transformation in MDS: ongoing challenges and future outlooks

0:04:44

Immunotherapy in MDS

0:01:13

Targeting p53 in MDS

0:01:59

The role of inflammatory signaling pathways in lower-risk MDS

0:02:49

Front-line treatment options for HR-MDS: can we move past azacitidine?

0:01:33

The current guidelines and therapies for TP53-mutated MDS and AML

0:01:17

Using an animated patient’s guide to improve understanding of MDS

0:01:07

Changing front-line therapy in MDS and AML

0:00:44

Responses to COVID-19 vaccination in patients with MDS and AML

0:03:06

The role of chronic inflammation in lower-risk MDS and future therapeutic strategies

0:09:25

Improving MDS management: new targets, drug combinations, and personalized and cellular therapies

0:01:38

The importance of targeting TP53 in AML and agents being explored

0:01:13

Expanding treatment options for AML to patients with MDS

0:01:03

Significance of p53 mutations in AML

1:29:40

Personalized Care in MDS: Integrating Innovative Treatments Into a Cohesive Patient Care Model